Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy

Lung cancer is the leading cause of cancer-related death worldwide [1]. In Taiwan, epidermal growth factor receptor (EGFR) mutations are the most common driver mutations and can be found in 55.7% of patients with lung adenocarcinoma [2]. In addition to the discovery of several important driver mutations, a number of agents targeting mutations in genes including EGFR, anaplastic lymphoma kinase (ALK), ROS1, MET, and RET, have been developed, with some demonstrating impressive clinical responses [3 –14].

Source: Lung Cancer - August 25, 2019 Category: Cancer & Oncology Authors: Min-Shu Hsieh, Mong-Wei Lin, Yi-Hsuan Lee Source Type: research